Skip to content
value.today
DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is listed today as DiaMedica Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of DiaMedica Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2025$30 MPrivate placement after listing$10 to $50 million

DiaMedica Therapeutics Inc.: Private sale, Jul 2025

Investors in this round

14 investors had bought by the notice of Jul 25, 2025: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • David J. Wambeke · Executive Officer
  • Lorianne Masuoka · Executive Officer
  • Rick Pauls · Executive Officer, Director
  • Scott Kellen · Executive Officer
  • Charles P. Semba · Director
  • Daniel T. O'Connor · Director
  • James T. Parsons · Director
  • Michael R. Giuffre · Director
  • Richard R. Kuntz · Director
  • Tanya N. Lewis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Kellen, Chief Financial Officer and Secretary. Newest notice filed Jul 25, 2025. Read the notice at the SEC.

equitySEC
Jun 2024$12 MPrivate placement after listing$10 to $50 million

DiaMedica Therapeutics Inc.: Private sale, Jun 2024

Investors in this round

10 investors had bought by the notice of Jul 2, 2024: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • David J. Wambeke · Executive Officer
  • Lorianne Masuoka · Executive Officer
  • Rick Pauls · Executive Officer, Director
  • Scott Kellen · Executive Officer
  • Charles P. Semba · Director
  • James T. Parsons · Director
  • R. Michael Giuffre · Director
  • Richard D. Pilnik · Director
  • Richard Michael Kuntz · Director
  • Tanya N. Lewis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Kellen, Chief Financial Officer and Secretary. Newest notice filed Jul 2, 2024. Read the notice at the SEC.

equitySEC
Jun 2023$38 MPrivate placement after listing$10 to $50 million

DiaMedica Therapeutics Inc.: Private sale, Jun 2023

Investors in this round

34 investors had bought by the notice of Jun 27, 2023: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $38 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$845,849
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • David J. Wambeke · Executive Officer
  • Dominic Cundari · Executive Officer
  • Julie Daves · Executive Officer
  • Kirsten Gruis · Executive Officer
  • Rick Pauls · Executive Officer, Director
  • Scott Kellen · Executive Officer
  • Charles P. Semba · Director
  • James T. Parsons · Director
  • R. Michael Giuffre · Director
  • Richard D. Pilnik · Director
  • Richard P. Kuntz · Director
  • Tanya N. Lewis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, MinnesotaSold in CA, CT, FL, KY, MN, NY

Signed by Scott Kellen, Chief Financial Officer and Secretary. Newest notice filed Jun 27, 2023. Read the notice at the SEC.

equitySEC
Sep 2021$30 MPrivate placement after listing$10 to $50 million

DiaMedica Therapeutics Inc.: Private sale, Sep 2021

Investors in this round

10 investors had bought by the notice of Oct 6, 2021: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Harry W. Alcorn Jr. · Executive Officer
  • Rick Pauls · Executive Officer, Director
  • Scott Kellen · Executive Officer
  • Sydney Gilman · Executive Officer
  • Amy L. Burroughs · Director
  • Charles P. Semba · Director
  • James T. Parsons · Director
  • R. Michael Giuffre · Director
  • Richard D. Pilnik · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Kellen, Chief Financial Officer and Secretary. Newest notice filed Oct 6, 2021. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • DiaMedica Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).

    SEC Form D · Jul 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2025

Products and services#

No products or services of DiaMedica Therapeutics Inc. are on record.

Investors#

No investor of DiaMedica Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding DiaMedica Therapeutics Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by DiaMedica Therapeutics Inc.
NameRoleNamed in
David J. WambekeExecutive officerJul 2025
Lorianne MasuokaExecutive officerJul 2025
Rick PaulsExecutive officerJul 2025
Scott KellenExecutive officerJul 2025
Dominic CundariExecutive officerJun 2023
Julie DavesExecutive officerJun 2023
Kirsten GruisExecutive officerJun 2023
Harry W. Alcorn Jr.Executive officerOct 2021
Sydney GilmanExecutive officerOct 2021
Charles P. SembaDirectorJul 2025
Daniel T. O'ConnorDirectorJul 2025
James T. ParsonsDirectorJul 2025
Michael R. GiuffreDirectorJul 2025
Richard R. KuntzDirectorJul 2025
Rick PaulsDirectorJul 2025
Tanya N. LewisDirectorJul 2025
R. Michael GiuffreDirectorJul 2024
Richard D. PilnikDirectorJul 2024
Richard Michael KuntzDirectorJul 2024
Richard P. KuntzDirectorJun 2023
Amy L. BurroughsDirectorOct 2021

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.